DDInter1266 DDInter997
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Ivacaftor
Naproxen {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Naproxen {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Naproxen {u} (Compound) binds {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) interacts with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Naproxen {u} (Compound) causes {v} (Side Effect) Oropharyngeal pain
Oropharyngeal pain {u} (Side Effect) is caused by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Naproxen {u} (Compound) causes {v} (Side Effect) Breast disorder
Breast disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Ivacaftor (Compound)
Naproxen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) interacts with ORM1 (Gene) and ORM1 (Gene) is bound by Ivacaftor (Compound)
Naproxen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ivacaftor (Compound)
Naproxen (Compound) binds UGT2B7 (Gene) and UGT2B7 (Gene) interacts with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Naproxen (Compound) causes Oropharyngeal pain (Side Effect) and Oropharyngeal pain (Side Effect) is caused by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Naproxen (Compound) causes Breast disorder (Side Effect) and Breast disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor